Thus, we discovered a mechanism of prostate cancer lineage plasticity that provides an effective prediction strategy utilizing gene expression-based biomarkers for NEPC development through the association of activated ZBTB46 and accumulated NGF via stimulation of the CHRM4–AKT–MYCN pathway. The gene discussed is CHRM4; the disease is prostate cancer.